XPC

Summary

XPC (XPC complex subunit, DNA damage recognition and repair factor, HGNC:12816) is a protein-coding gene on chromosome 3p25.1, encoding DNA repair protein complementing XP-C cells (Q01831). Involved in global genome nucleotide excision repair (GG-NER) by acting as damage sensing and DNA-binding factor component of the XPC complex.

The protein encoded by this gene is a key component of the XPC complex, which plays an important role in the early steps of global genome nucleotide excision repair (NER). The encoded protein is important for damage sensing and DNA binding, and shows a preference for single-stranded DNA. Mutations in this gene or some other NER components can result in Xeroderma pigmentosum, a rare autosomal recessive disorder characterized by increased sensitivity to sunlight with the development of carcinomas at an early age. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 7508 — RefSeq curated summary.

At a glance

• Gene–disease (curated): xeroderma pigmentosum group C (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 1,097 total — 109 pathogenic, 82 likely-pathogenic
• Phenotypes (HPO): 68
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_004628

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12816
Approved symbol	XPC
Name	XPC complex subunit, DNA damage recognition and repair factor
Location	3p25.1
Locus type	gene with protein product
Status	Approved
Aliases	XPCC, RAD4
Ensembl gene	ENSG00000154767
Ensembl biotype	protein_coding
OMIM	613208
Entrez	7508

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 11 protein_coding, 4 retained_intron, 3 nonsense_mediated_decay

ENST00000285021, ENST00000427795, ENST00000452172, ENST00000455144, ENST00000476581, ENST00000477324, ENST00000511155, ENST00000850573, ENST00000850574, ENST00000850575, ENST00000887849, ENST00000887850, ENST00000887851, ENST00000887852, ENST00000887853, ENST00000933890, ENST00000933891, ENST00000933892

RefSeq mRNA: 5 — MANE Select: NM_004628 NM_001354726, NM_001354727, NM_001354729, NM_001354730, NM_004628

CCDS: CCDS46763

Canonical transcript exons

ENST00000285021 — 16 exons

Exon	Start	End
ENSE00001160407	14170438	14170550
ENSE00001160413	14172867	14173062
ENSE00003656671	14168257	14168380
ENSE00004282168	14148562	14148731
ENSE00004282170	14167169	14167253
ENSE00004282171	14148814	14148948
ENSE00004282173	14159741	14159830
ENSE00004282174	14158011	14158892
ENSE00004282176	14164813	14164933
ENSE00004282177	14152335	14152416
ENSE00004282180	14165428	14165585
ENSE00004282181	14147290	14147379
ENSE00004282182	14147908	14148001
ENSE00004282183	14156335	14156495
ENSE00004282184	14178466	14178601
ENSE00004282186	14145147	14146159

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 97.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.5264 / max 629.6482, expressed in 1817 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41217	31.5001	1815
41218	0.8807	560
41216	0.1456	72

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	97.30	gold quality
calcaneal tendon	UBERON:0003701	96.16	gold quality
mucosa of stomach	UBERON:0001199	93.12	gold quality
skin of leg	UBERON:0001511	93.03	gold quality
left ovary	UBERON:0002119	92.97	gold quality
endocervix	UBERON:0000458	92.79	gold quality
nerve	UBERON:0001021	92.66	gold quality
tibial nerve	UBERON:0001323	92.66	gold quality
right ovary	UBERON:0002118	92.59	gold quality
left lobe of thyroid gland	UBERON:0001120	92.46	gold quality
body of uterus	UBERON:0009853	92.39	gold quality
right uterine tube	UBERON:0001302	92.29	gold quality
skin of abdomen	UBERON:0001416	92.29	gold quality
thyroid gland	UBERON:0002046	92.20	gold quality
right lobe of thyroid gland	UBERON:0001119	92.04	gold quality
popliteal artery	UBERON:0002250	91.95	gold quality
tibial artery	UBERON:0007610	91.94	gold quality
pituitary gland	UBERON:0000007	91.82	gold quality
adenohypophysis	UBERON:0002196	91.69	gold quality
right lung	UBERON:0002167	91.68	gold quality
zone of skin	UBERON:0000014	91.62	gold quality
artery	UBERON:0001637	91.62	gold quality
descending thoracic aorta	UBERON:0002345	91.51	gold quality
aorta	UBERON:0000947	91.42	gold quality
middle frontal gyrus	UBERON:0002702	91.41	gold quality
ectocervix	UBERON:0012249	91.25	gold quality
body of pancreas	UBERON:0001150	90.91	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.90	gold quality
ascending aorta	UBERON:0001496	90.78	gold quality
thoracic aorta	UBERON:0001515	90.78	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.13
E-HCAD-5	no	2.21

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
CASP2	Repression
CPD	Unknown
KIN	Activation
RNF111	Repression

Upstream regulators (CollecTRI, top): BRCA1, CREB1, E2F1, E2F4, FOXC1, HIF1A, NR1H2, SIRT1, SP1, TFDP1, TP53, TP63

miRNA regulators (miRDB)

34 targeting XPC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-4695-5P	99.06	64.87	1151
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-628-3P	99.04	68.37	814
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-3620-3P	97.78	64.88	772
HSA-MIR-6879-5P	97.77	65.52	1521

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• we investigated the association between the repair phenotype of ultraviolet (UV)-induced damage and genotypes of three DNA repair genes, XPC and XPD [involved in nucleotide excision repair (NER)] and XRCC1 [involved in base excision repair (BER)]. (PMID:11872635)
• human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function (PMID:12177305)
• XPC is regulated by DNA damage and p53 (PMID:12242345)
• the multistep process of DNA damage recognition includes initiation by XPC-hHR23B, which is then replaced by the combined action of XPA and RPA (PMID:12486030)
• BRCA1 upregulates XPC, with some evidence that p53 is involved in its regulation. (PMID:12496474)
• interacts physically and functionally with thymine DNA glycosylase (PMID:12505994)
• XPC and TFIIH are recruited to DNA damage by TP53 (PMID:12713809)
• analysis of mHR23A/B double-mutant cells showed that HR23 proteins function in nucleotide excision repair by governing xeroderma pigmentosum group C protein stability via partial protection against proteasomal degradation (PMID:12815074)
• Analysis of the XPC sequence (940 residues), using a calmodulin target recognition software, enabled us to predict two putative binding sites for centrin-2 (PMID:12890685)
• DDB2p48 activates the recruitment of XPC to cyclobutane pyrimidine dimers and may be the initial recognition factor in the nucleotide excision repair pathway (PMID:12944386)
• important role of the XPC protein in the cancer prevention (PMID:15107491)
• XPC protein plays an important role in the cisplatin treatment-mediated cellular response and may suggest a possible mechanism of cancer cell drug resistance. (PMID:15353127)
• presence of nucleosomes in undamaged DNA regions may help specific binding of the XPC complex to damaged sites by excluding its non-specific binding to undamaged DNA regions (PMID:15661662)
• Genetic polymorphism in XPC gene is associated with lung cancer (PMID:15700316)
• XPC undergoes reversible ubiquitylation upon UV irradiation and this depends on the presence of functional UV-DDB activity. (PMID:15882621)
• Overexpression of XPC is associated with liver fibrogenesis and cancer and could be related to the well recognized resistance of HCC to chemotherapeutics. (PMID:15922480)
• Centrin 2 stimulates nucleotide excision repair by interacting with XPC. (PMID:15964821)
• Reduced XPC mRNA levels and mutations are associated with xeroderma pigmentosum risk (PMID:16081512)
• The findings support the hypothesis that these two XPC variants may contribute to the risk of developing lung cancer. (PMID:16086280)
• RAD23 homolog A regulates the function of XPC by its association with the nucleotide excision repair activator p53 (PMID:16105547)
• Three linked XPC alleles, 492R, 499A, and 939Q, were associated with increased risk of colorectal adenoma in smokers. (PMID:16492920)
• CUL-4A mediates the proteolytic degradation of DDB2 and this degradation event, initiated at the lesion sites, regulates damage recognition by XPC. (PMID:16527807)
• the crystal structure of calcium-loaded full-length centrin-2 complexed with a xeroderma pigmentosum group C peptide; a novel binding motif for centrin (PMID:16627479)
• A novel homozygous complex insertion/deletion mutation within exon 9 of the XPC gene in Iraqi family with xeroderma pigmentosum was reproted. (PMID:16794584)
• A complex formed by a Ca2+-bound human centrin 2 with a 17-mer peptide derived from the XPC sequence was crystallized. (PMID:16820684)
• This article summarizes our current knowledge of the properties of the XPC complex and UV-DDB and discusses possible roles for ubiquitylation in the molecular mechanisms that underlie the efficient recognition and repair of DNA damage. (PMID:16858626)
• XPC plays an unexpected and multifaceted role in cell protection from oxidative DNA damage. (PMID:16957781)
• In the high incidence region of Hebei Province, C/T genotype of XPC exon 8 may decrease the risk of developing gastsric cardiac adenocarcinoma. (PMID:16965652)
• sequence variants in the XPC gene may modulate the risk of bladder cancer. (PMID:17052994)
• Results show that hypermethylation of the XPC promoter may play a crucial role in XPC inactivation, which may partly contribute to the occurrence of p53 mutations during lung tumorigenesis, especially nonsmokers. (PMID:17325666)
• statistically significant interaction between the XPC Lys939Gln polymorphism and consumption of red meat, with a 3.7-fold increase in colorectal cancer risk per 100g red meat intake per day among carriers of the homozygous variant (PMID:17363013)
• XPC polymorphism might affect p53 alteration and the molecular pathway defined by the p53 alteration in the development of muscle-invasive bladder cancer (PMID:17374967)
• XPC (K939Q) polymorphism either individually or in combination with the XPD (K751Q) polymorphism modulates the risk of death in patients with urinary bladder neoplasms (PMID:17438703)
• results suggest that inherited sequence variations in XPC may modulate risk of lung cancer, especially lung adenocarcinoma, in Chinese populations (PMID:17498315)
• Results suggest that reduced XPC mRNA level may constitute an independent prognostic factor for nonsmall cell lung cancer patients. (PMID:17508409)
• Single nucleotide polymorphisms of xeroderma pigmentosum group C is associated with esophageal squamous cell carcinoma (PMID:17653764)
• predictive value of DNA damage-induced XPC levels as a possible biomarker for radiosensitivity has to be further investigated (PMID:17657713)
• Results demonstrate the role of DNA binding by xeroderma pigmentosum C protein in the assembly of subsequent nucleotide excision repair intermediate complexes. (PMID:17682058)
• Only carriers of the XPC 499Val/Val genotype had a significantly increased SCCHN risk. (PMID:17684138)
• The XPC 499Val allele and its haplotype were strongly associated with nasopharyngeal carcinoma. This polymorphism may be a contributing factor in NPC development. (PMID:17882560)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	xpc	ENSDARG00000039754
mus_musculus	Xpc	ENSMUSG00000030094
rattus_norvegicus	Xpc	ENSRNOG00000008274
drosophila_melanogaster	Xpc	FBGN0004698
caenorhabditis_elegans		WBGENE00022296

Protein

Protein identifiers

DNA repair protein complementing XP-C cells — Q01831 (reviewed: Q01831)

Alternative names: Xeroderma pigmentosum group C-complementing protein, p125

All UniProt accessions (3): Q01831, E7EUB5, X5DRB1

UniProt curated annotations — full annotation on UniProt →

Function. Involved in global genome nucleotide excision repair (GG-NER) by acting as damage sensing and DNA-binding factor component of the XPC complex. Has only a low DNA repair activity by itself which is stimulated by RAD23B and RAD23A. Has a preference to bind DNA containing a short single-stranded segment but not to damaged oligonucleotides. This feature is proposed to be related to a dynamic sensor function: XPC can rapidly screen duplex DNA for non-hydrogen-bonded bases by forming a transient nucleoprotein intermediate complex which matures into a stable recognition complex through an intrinsic single-stranded DNA-binding activity. The XPC complex is proposed to represent the first factor bound at the sites of DNA damage and together with other core recognition factors, XPA, RPA and the TFIIH complex, is part of the pre-incision (or initial recognition) complex. The XPC complex recognizes a wide spectrum of damaged DNA characterized by distortions of the DNA helix such as single-stranded loops, mismatched bubbles or single-stranded overhangs. The orientation of XPC complex binding appears to be crucial for inducing a productive NER. XPC complex is proposed to recognize and to interact with unpaired bases on the undamaged DNA strand which is followed by recruitment of the TFIIH complex and subsequent scanning for lesions in the opposite strand in a 5’-to-3’ direction by the NER machinery. Cyclobutane pyrimidine dimers (CPDs) which are formed upon UV-induced DNA damage esacpe detection by the XPC complex due to a low degree of structural perurbation. Instead they are detected by the UV-DDB complex which in turn recruits and cooperates with the XPC complex in the respective DNA repair. In vitro, the XPC:RAD23B dimer is sufficient to initiate NER; it preferentially binds to cisplatin and UV-damaged double-stranded DNA and also binds to a variety of chemically and structurally diverse DNA adducts. XPC:RAD23B contacts DNA both 5’ and 3’ of a cisplatin lesion with a preference for the 5’ side. XPC:RAD23B induces a bend in DNA upon binding. XPC:RAD23B stimulates the activity of DNA glycosylases TDG and SMUG1. In absence of DNA repair, the XPC complex also acts as a transcription coactivator: XPC interacts with the DNA-binding transcription factor E2F1 at a subset of promoters to recruit KAT2A and histone acetyltransferase complexes (HAT). KAT2A recruitment specifically promotes acetylation of histone variant H2A.Z.1/H2A.Z, but not H2A.Z.2/H2A.V, thereby promoting expression of target genes.

Subunit / interactions. Component of the XPC complex composed of XPC, RAD23B and CETN2. Interacts with RAD23A; the interaction is suggesting the existence of a functional equivalent variant XPC complex. Interacts with TDG; the interaction is demonstrated using the XPC:RAD23B dimer. Interacts with SMUG1; the interaction is demonstrated using the XPC:RAD23B dimer. Interacts with DDB2. Interacts with CCNH, GTF2H1 and ERCC3. Interacts with E2F1 and KAT2A; leading to KAT2A recruitment to promoters and subsequent acetylation of histones.

Subcellular location. Nucleus. Chromosome. Cytoplasm.

Post-translational modifications. Ubiquitinated upon UV irradiation; the ubiquitination requires the UV-DDB complex, appears to be reversible and does not serve as a signal for degradation. Ubiquitinated by RNF11 via ‘Lys-63’-linked ubiquitination. Ubiquitination by RNF111 is polysumoylation-dependent and promotes nucleotide excision repair. Sumoylated; sumoylation promotes ubiquitination by RNF111.

Disease relevance. Xeroderma pigmentosum complementation group C (XP-C) [MIM:278720] An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. The skin develops marked freckling and other pigmentation abnormalities. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the XPC family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q01831-1	1	yes
Q01831-2	2
Q01831-3	3, B

RefSeq proteins (5): NP_001341655, NP_001341656, NP_001341658, NP_001341659, NP_004619* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004583	DNA_repair_Rad4	Family
IPR018026	DNA_repair_Rad4-like	Family
IPR018325	Rad4/PNGase_transGLS-fold	Domain
IPR018326	Rad4_beta-hairpin_dom1	Domain
IPR018327	BHD_2	Domain
IPR018328	Rad4_beta-hairpin_dom3	Domain
IPR036985	Transglutaminase-like_sf	Homologous_superfamily
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR042488	Rad4_BHD3_sf	Homologous_superfamily

Pfam: PF03835, PF10403, PF10404, PF10405

UniProt features (79 total): sequence variant 18, modified residue 14, mutagenesis site 11, region of interest 10, compositionally biased region 5, helix 5, cross-link 4, splice variant 3, sequence conflict 2, turn 2, strand 2, initiator methionine 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

18 structures.

PDB	Method	Resolution (Å)
2OBH	X-RAY DIFFRACTION	1.8
2GGM	X-RAY DIFFRACTION	2.35
28JM	ELECTRON MICROSCOPY	3.29
8EBU	ELECTRON MICROSCOPY	3.3
9PD3	ELECTRON MICROSCOPY	3.3
28JS	ELECTRON MICROSCOPY	3.32
9XYU	ELECTRON MICROSCOPY	3.5
28KE	ELECTRON MICROSCOPY	3.6
8EBX	ELECTRON MICROSCOPY	3.6
8EBY	ELECTRON MICROSCOPY	3.6
8EBT	ELECTRON MICROSCOPY	3.9
28JV	ELECTRON MICROSCOPY	3.91
8EBS	ELECTRON MICROSCOPY	4
9PCP	ELECTRON MICROSCOPY	4.3
8EBW	ELECTRON MICROSCOPY	5.6
8EBV	ELECTRON MICROSCOPY	7.1
2A4J	SOLUTION NMR
2RVB	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01831-F1	67.67	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (18): 94, 129, 140, 169, 397, 398, 399, 453, 460, 876, 883, 884, 891, 903, 41, 81, 89, 161

Mutagenesis-validated functional residues (11):

Position	Phenotype
531	slightly diminishes repair activity and slightly impairs dna binding.
542	slightly diminishes repair activity and slightly impairs dna binding.
733	diminishes repair activity and impairs dna binding.
754	reduces dna repair activity; abolishes single-stranded dna binding; reduces binding to homoduplex dna; reduces localizat
755	reduces nuclear mobility and impairs repair activity.
756	reduces dna repair activity; abolishes single-stranded dna binding; reduces binding to homoduplex dna; reduces localizat
797	reduces dna repair activity; abolishes single-stranded dna binding; reduces binding to homoduplex dna; reduces localizat
799	reduces dna repair activity; abolishes single-stranded dna binding; reduces binding to homoduplex dna; greatly reduces l
848	reduces ner activity and abolishes interaction with cetn2; when associated with a-851 and a-855.
851	reduces ner activity and abolishes interaction with cetn2; when associated with a-848 and a-855.
855	reduces ner activity and abolishes interaction with cetn2; when associated with a-848 and a-851.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3108214	SUMOylation of DNA damage response and repair proteins
R-HSA-5696394	DNA Damage Recognition in GG-NER
R-HSA-5696395	Formation of Incision Complex in GG-NER

MSigDB gene sets: 375 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER, MULLIGHAN_NPM1_SIGNATURE_3_UP, JI_RESPONSE_TO_FSH_UP, GOBP_CELLULAR_RESPONSE_TO_UV, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, GOBP_CELL_CYCLE_PHASE_TRANSITION, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, DARWICHE_PAPILLOMA_PROGRESSION_RISK, KAUFFMANN_DNA_REPAIR_GENES, MORF_PSMC2, GOBP_MITOTIC_INTRA_S_DNA_DAMAGE_CHECKPOINT_SIGNALING, HINATA_NFKB_TARGETS_KERATINOCYTE_UP, GOBP_NUCLEOTIDE_EXCISION_REPAIR, MORF_RAF1

GO Biological Process (14): pyrimidine dimer repair by nucleotide-excision repair (GO:0000720), DNA repair (GO:0006281), nucleotide-excision repair (GO:0006289), mismatch repair (GO:0006298), response to xenobiotic stimulus (GO:0009410), response to UV-B (GO:0010224), response to auditory stimulus (GO:0010996), mitotic intra-S DNA damage checkpoint signaling (GO:0031573), positive regulation of DNA-templated transcription (GO:0045893), UV-damage excision repair (GO:0070914), regulation of mitotic cell cycle phase transition (GO:1901990), DNA damage response (GO:0006974), regulation of mitotic cell cycle (GO:0007346), regulation of cell cycle phase transition (GO:1901987)

GO Molecular Function (10): heteroduplex DNA loop binding (GO:0000404), bubble DNA binding (GO:0000405), damaged DNA binding (GO:0003684), single-stranded DNA binding (GO:0003697), transcription coactivator activity (GO:0003713), protein-containing complex binding (GO:0044877), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), DNA damage sensor activity (GO:0140612), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (13): nucleotide-excision repair complex (GO:0000109), nucleotide-excision repair factor 2 complex (GO:0000111), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), plasma membrane (GO:0005886), XPC complex (GO:0071942), site of DNA damage (GO:0090734), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Global Genome Nucleotide Excision Repair (GG-NER)	2
SUMO E3 ligases SUMOylate target proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
DNA repair	3
DNA secondary structure binding	2
DNA binding	2
binding	2
nucleotide-excision repair complex	2
chromosome	2
intracellular membrane-bounded organelle	2
nuclear lumen	2
intracellular membraneless organelle	2
cytoplasm	2
nucleotide-excision repair	1
pyrimidine dimer repair	1
DNA metabolic process	1
DNA damage response	1
response to chemical	1
response to UV	1
response to mechanical stimulus	1
mitotic S phase	1
mitotic DNA damage checkpoint signaling	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cellular response to UV	1
regulation of mitotic cell cycle	1
mitotic cell cycle phase transition	1
regulation of cell cycle phase transition	1
cellular response to stress	1
mitotic cell cycle	1
regulation of cell cycle	1
regulation of cell cycle process	1
cell cycle phase transition	1
DNA insertion or deletion binding	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
DNA-binding transcription factor binding	1
damaged DNA binding	1
molecular sensor activity	1
nucleic acid binding	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1435 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
XPC	RAD23B	P54727	999
XPC	CETN2	P41208	992
XPC	SMARCB1	Q12824	957
XPC	RAD23A	P54725	950
XPC	ERCC1	P07992	945
XPC	XPA	P23025	918
XPC	FEN1	P39748	910
XPC	ERCC4	Q92889	798
XPC	DDB2	Q92466	797
XPC	DDB1	Q16531	791
XPC	TDG	Q13569	766
XPC	TOPBP1	Q92547	760
XPC	ERCC3	P19447	737
XPC	ERCC6	Q03468	718
XPC	ERCC2	P18074	715

IntAct

170 interactions, top by confidence:

A	B	Type	Score
XPC	RAD23B	psi-mi:“MI:0915”(physical association)	0.900
XPC	CETN2	psi-mi:“MI:0407”(direct interaction)	0.900
CCNH	ERCC3	psi-mi:“MI:0914”(association)	0.850
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
H2AZ1	ZNHIT1	psi-mi:“MI:0914”(association)	0.770
CETN2	SFI1	psi-mi:“MI:0914”(association)	0.740
RPA4	RPA1	psi-mi:“MI:0914”(association)	0.740
H2AX	PPM1G	psi-mi:“MI:0914”(association)	0.730
XPC	CETN3	psi-mi:“MI:0914”(association)	0.730
XPC	PARP1	psi-mi:“MI:0914”(association)	0.730
CETN2	RAD23B	psi-mi:“MI:0914”(association)	0.670
RAD23B	CETN2	psi-mi:“MI:0914”(association)	0.670
H2AC4	PPM1G	psi-mi:“MI:0914”(association)	0.670
	XPC	psi-mi:“MI:0915”(physical association)	0.640

BioGRID (311): RAD23B (Co-fractionation), RAD23B (Affinity Capture-Western), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), XPC (Affinity Capture-MS), TDG (Two-hybrid), XPC (Two-hybrid), XPC (Reconstituted Complex), XPC (Proximity Label-MS)

ESM2 similar proteins: A4FV97, D4ACP5, O09130, O35144, O76021, P38432, P51612, Q01831, Q05CL8, Q08288, Q14684, Q15554, Q28G87, Q32LC1, Q58CQ0, Q58CQ5, Q5I0E6, Q5NC05, Q5NVA9, Q5R8S0, Q5RCE6, Q5RDL2, Q5SU73, Q5SXM2, Q5XI01, Q5ZJJ1, Q66H19, Q66H85, Q6AYK5, Q6IRU7, Q7TSG2, Q80UU1, Q8BJW7, Q8BVY0, Q8N163, Q8VDP4, Q8VID5, Q91VE6, Q91YK2, Q96AY2

Diamond homologs: P51612, P87235, Q01831, Q10445, Q24595, Q8W489

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ATR	up-regulates	XPC	binding
CSNK2A1	“up-regulates activity”	XPC	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 154 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of Incision Complex in GG-NER	14	34.2×	9e-16
Dual Incision in GG-NER	10	25.0×	4e-10
PCNA-Dependent Long Patch Base Excision Repair	5	25.0×	1e-05
RNA Polymerase I Transcription Termination	7	22.0×	3e-07
RNA Polymerase I Promoter Escape	16	18.7×	4e-14
FXIIa activates plasma kallikrein-kinin system	11	18.3×	1e-09
SIRT1 negatively regulates rRNA expression	11	18.0×	1e-09
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	10	17.7×	8e-09

GO biological processes:

GO term	Partners	Fold	FDR
base-excision repair	10	34.2×	9e-11
nucleotide-excision repair	12	33.5×	8e-13
double-strand break repair via nonhomologous end joining	5	15.4×	2e-03
heterochromatin formation	8	14.9×	1e-05
response to UV	5	13.4×	3e-03
telomere maintenance	6	11.7×	1e-03
nucleosome assembly	11	11.3×	9e-07
cytoplasmic translation	7	9.5×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

1097 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	109
Likely pathogenic	82
Uncertain significance	195
Likely benign	567
Benign	47

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1074604	NM_004628.5(XPC):c.2224C>T (p.Gln742Ter)	Pathogenic
1074884	NM_004628.5(XPC):c.1452dup (p.Arg485fs)	Pathogenic
1076552	NM_004628.5(XPC):c.875_882dup (p.Asp295fs)	Pathogenic
1319091	NM_004628.5(XPC):c.299+2T>G	Pathogenic
1342722	NM_004628.5(XPC):c.2250+1G>A	Pathogenic
1354436	NM_004628.5(XPC):c.803dup (p.Asn268fs)	Pathogenic
1366319	NM_004628.5(XPC):c.1527del (p.Gly510fs)	Pathogenic
1380921	NM_004628.5(XPC):c.1988_1989del (p.Thr663fs)	Pathogenic
1413330	NM_004628.5(XPC):c.1681dup (p.Tyr561fs)	Pathogenic
1451431	NM_004628.5(XPC):c.529_530del (p.Glu177fs)	Pathogenic
1453010	NM_004628.5(XPC):c.826C>T (p.Gln276Ter)	Pathogenic
1453188	NM_004628.5(XPC):c.220A>T (p.Lys74Ter)	Pathogenic
1455403	NM_004628.5(XPC):c.2028C>G (p.Tyr676Ter)	Pathogenic
1455510	NM_004628.5(XPC):c.2473dup (p.Trp825fs)	Pathogenic
1455531	NM_004628.5(XPC):c.1302_1303del (p.Ser434fs)	Pathogenic
1456131	NM_004628.5(XPC):c.1182del (p.Ser394fs)	Pathogenic
1458152	NM_004628.5(XPC):c.570del (p.Arg191fs)	Pathogenic
1675906	NM_004628.5(XPC):c.1024del (p.Asp342fs)	Pathogenic
1701453	NM_004628.5(XPC):c.2451_2461delinsT (p.Lys818fs)	Pathogenic
190208	NM_004628.5(XPC):c.2262del (p.Asn754fs)	Pathogenic
190209	NM_004628.5(XPC):c.622-2A>C	Pathogenic
190211	NM_004628.5(XPC):c.1677C>A (p.Tyr559Ter)	Pathogenic
190213	NM_004628.5(XPC):c.2251-1G>C	Pathogenic
1951736	NM_004628.5(XPC):c.2368dup (p.Cys790fs)	Pathogenic
1968545	NM_004628.5(XPC):c.2474G>A (p.Trp825Ter)	Pathogenic
2007576	NM_004628.5(XPC):c.553dup (p.Glu185fs)	Pathogenic
2078189	NM_004628.5(XPC):c.1919_1923dup (p.Lys642fs)	Pathogenic
2124748	NM_004628.5(XPC):c.2226del (p.Gln742fs)	Pathogenic
2425189	NC_000003.11:g.(?14206293)(14209904_?)del	Pathogenic
254	NM_004628.4(XPC):c.621_622ins83 (p.?)	Pathogenic

SpliceAI

2634 predictions. Top by Δscore:

Variant	Effect	Δscore
3:14146168:G:GC	acceptor_gain	1.0000
3:14146172:CAG:C	acceptor_gain	1.0000
3:14146173:A:T	acceptor_gain	1.0000
3:14146174:G:C	acceptor_gain	1.0000
3:14146174:G:GC	acceptor_gain	1.0000
3:14146177:G:C	acceptor_gain	1.0000
3:14146177:G:GC	acceptor_gain	1.0000
3:14147285:CTGA:C	donor_loss	1.0000
3:14147286:TGAC:T	donor_loss	1.0000
3:14147287:GACCT:G	donor_loss	1.0000
3:14147289:C:G	donor_loss	1.0000
3:14147375:TTTTT:T	acceptor_gain	1.0000
3:14147376:TTTT:T	acceptor_gain	1.0000
3:14147377:TTT:T	acceptor_gain	1.0000
3:14147378:TT:T	acceptor_gain	1.0000
3:14147379:TC:T	acceptor_loss	1.0000
3:14147380:C:CC	acceptor_gain	1.0000
3:14147381:T:A	acceptor_loss	1.0000
3:14147387:C:CT	acceptor_gain	1.0000
3:14147388:A:T	acceptor_gain	1.0000
3:14147392:A:AC	acceptor_gain	1.0000
3:14147392:A:C	acceptor_gain	1.0000
3:14147903:CTTA:C	donor_loss	1.0000
3:14147904:TTA:T	donor_loss	1.0000
3:14147905:TACC:T	donor_loss	1.0000
3:14147906:A:AC	donor_gain	1.0000
3:14147906:ACCT:A	donor_gain	1.0000
3:14147907:C:CC	donor_gain	1.0000
3:14147907:CCT:C	donor_gain	1.0000
3:14147907:CCTC:C	donor_gain	1.0000

AlphaMissense

6165 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:14148591:A:C	F797L	0.999
3:14148591:A:T	F797L	0.999
3:14148593:A:G	F797L	0.999
3:14147984:A:T	V813D	0.998
3:14148634:G:T	A783D	0.998
3:14148679:G:T	P768H	0.998
3:14152382:A:G	W690R	0.998
3:14152382:A:T	W690R	0.998
3:14156344:A:T	V675D	0.998
3:14147960:A:T	L821H	0.997
3:14148669:A:C	C771W	0.997
3:14148679:G:C	P768R	0.997
3:14148720:G:C	N754K	0.997
3:14148720:G:T	N754K	0.997
3:14148827:G:T	A746D	0.997
3:14148712:C:A	G757V	0.996
3:14148730:A:T	V751E	0.996
3:14156396:C:G	A658P	0.996
3:14148671:A:G	C771R	0.995
3:14148680:G:A	P768S	0.995
3:14148712:C:T	G757E	0.995
3:14148714:A:C	F756L	0.995
3:14148714:A:T	F756L	0.995
3:14148716:A:G	F756L	0.995
3:14148853:C:A	Q737H	0.995
3:14148853:C:G	Q737H	0.995
3:14148865:A:C	F733L	0.995
3:14148865:A:T	F733L	0.995
3:14148867:A:G	F733L	0.995
3:14147352:A:G	W848R	0.994

dbSNP variants (sampled 300 via entrez): RS1000007221 (3:14169361 G>A), RS1000012162 (3:14146326 C>G,T), RS1000179716 (3:14151537 G>A), RS1000212459 (3:14166611 C>A), RS1000245836 (3:14147830 G>A,T), RS1000329584 (3:14157572 C>T), RS1000381937 (3:14157281 A>C,G), RS1000409652 (3:14179791 A>G), RS1000543405 (3:14163519 T>C), RS1000549110 (3:14169894 G>A,C), RS1000602863 (3:14169503 A>G), RS1000621206 (3:14151580 C>T), RS1000669774 (3:14158893 C>T), RS1000809363 (3:14175950 C>T), RS1000971305 (3:14165105 T>A,C)

Disease associations

OMIM: gene MIM:613208 | disease phenotypes: MIM:278720, MIM:278700, MIM:167000, MIM:176807

GenCC curated gene-disease

Disease	Classification	Inheritance
xeroderma pigmentosum group C	Definitive	Autosomal recessive
xeroderma pigmentosum	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
xeroderma pigmentosum group C	Definitive	AR

Mondo (6): xeroderma pigmentosum group C (MONDO:0010211), xeroderma pigmentosum (MONDO:0019600), ovarian cancer (MONDO:0008170), xeroderma pigmentosum group A (MONDO:0010210), prostate cancer, hereditary (MONDO:0700275), hereditary neoplastic syndrome (MONDO:0015356)

Orphanet (6): Xeroderma pigmentosum (Orphanet:910), Rare ovarian cancer (Orphanet:213500), Familial prostate cancer (Orphanet:1331), Inherited cancer-predisposing syndrome (Orphanet:140162), OBSOLETE: Xeroderma pigmentosum complementation group C (Orphanet:276255), OBSOLETE: Xeroderma pigmentosum complementation group A (Orphanet:276249)

HPO phenotypes

68 total (30 of 68 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000135	Hypogonadism
HP:0000164	Abnormality of the dentition
HP:0000252	Microcephaly
HP:0000365	Hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000486	Strabismus
HP:0000491	Keratitis
HP:0000498	Blepharitis
HP:0000509	Conjunctivitis
HP:0000518	Cataract
HP:0000524	Conjunctival telangiectasia
HP:0000613	Photophobia
HP:0000621	Entropion
HP:0000648	Optic atrophy
HP:0000656	Ectropion
HP:0000958	Dry skin
HP:0000962	Hyperkeratosis
HP:0000963	Thin skin
HP:0000992	Cutaneous photosensitivity
HP:0000995	Melanocytic nevus
HP:0001009	Telangiectasia
HP:0001010	Hypopigmentation of the skin
HP:0001029	Poikiloderma
HP:0001034	Hypermelanotic macule
HP:0001053	Hypopigmented skin patches
HP:0001059	Pterygium
HP:0001072	Thickened skin
HP:0001249	Intellectual disability

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90020028_790	Hip circumference adjusted for BMI	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D014983	Xeroderma Pigmentosum	C04.834.867; C16.131.831.936; C16.320.850.970; C17.800.600.925; C17.800.621.936; C17.800.804.936; C17.800.827.970; C18.452.284.975
C537243	Prostate cancer, familial (supp.)
C567886	Xeroderma Pigmentosum, Complementation Group C (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

5 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2228000	Toxicity	3	Platinum compounds	Gastrointestinal toxicity;Hematologic Disorder;Leukopenia;Non-Small Cell Lung Carcinoma
rs2228001	Toxicity	3	cisplatin	Neutropenia;Urinary Bladder Neoplasms
rs2228001	Toxicity	3	cisplatin	Drug Toxicity;Urinary Bladder Neoplasms
rs2228001	Toxicity	3	doxorubicin	Infectious disease;Osteosarcoma
rs2228001	Toxicity	3	cisplatin	Neoplasms;Osteosarcoma;Ototoxicity;Testicular Neoplasms

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2228001	TMEM43, XPC	3	2.75	4	cisplatin;doxorubicin
rs1870134	LSM3, XPC		0.00	0
rs2228000	XPC	3	1.50	1	Platinum compounds

CTD chemical–gene interactions

86 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases response to substance, decreases expression, decreases reaction, increases abundance, increases expression (+2 more)	12
Cisplatin	decreases expression, decreases reaction, increases expression, increases response to substance, affects reaction (+2 more)	9
Benzo(a)pyrene	decreases reaction, affects response to substance, affects cotreatment, decreases expression, increases expression	7
Aflatoxin B1	affects expression, affects cotreatment, increases expression	5
Arsenic	affects expression, decreases expression, decreases reaction, increases abundance, affects response to substance	4
Tobacco Smoke Pollution	decreases expression, increases expression	4
Doxorubicin	affects reaction, affects response to substance, affects expression, increases expression	3
bisphenol A	decreases expression, decreases methylation	2
Arsenic Trioxide	affects response to substance	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects response to substance	2
Benzene	decreases expression, increases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance, increases expression	2
Pesticides	decreases expression, affects response to substance	2
Quercetin	increases expression, affects response to substance	2
Valproic Acid	affects expression, affects binding, increases reaction, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	2
Zidovudine	decreases response to substance, increases expression	2
Cadmium Chloride	decreases expression	2
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
pradimicin-IRD	increases expression	1
2,4,6-tribromophenol	decreases expression	1
chloroacetaldehyde	decreases expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
pirinixic acid	increases activity, increases expression, affects binding	1
Nonidet P-40	decreases expression	1
tetrabromobisphenol A	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	affects cotreatment, decreases expression	1
4-hydroxy-2-nonenal	decreases expression	1
coumarin	decreases phosphorylation	1

Cellosaurus cell lines

170 cell lines: 108 finite cell line, 52 transformed cell line, 8 cancer cell line, 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1F18	XPH310BE LCL	Transformed cell line	Female
CVCL_1F27	XPH206BE LCL	Transformed cell line	Male
CVCL_1F32	XPH207BE LCL	Transformed cell line	Female
CVCL_1F33	XP67TMA	Finite cell line	Male
CVCL_1F34	XP68TMA	Finite cell line	Female
CVCL_1F35	XP69TMA LCL	Transformed cell line	Male
CVCL_1F36	XP69TMA	Finite cell line	Male
CVCL_1F37	XP72TMA LCL	Transformed cell line	Female
CVCL_1F38	XP72TMA	Finite cell line	Female
CVCL_1F39	XP73TMA LCL	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	PHASE4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	PHASE4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00001806	PHASE3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	PHASE3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	PHASE3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	PHASE3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002894	PHASE3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003214	PHASE3	COMPLETED	Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
NCT00003322	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003644	PHASE3	COMPLETED	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer